Comparative Pharmacology
Head-to-head clinical analysis: ARMODAFINIL versus DYANAVEL XR 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMODAFINIL versus DYANAVEL XR 20.
ARMODAFINIL vs DYANAVEL XR 20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armodafinil is a wakefulness-promoting agent. Its mechanism is unclear but may involve inhibition of dopamine reuptake, leading to increased extracellular dopamine levels. It also affects orexin, histamine, norepinephrine, and GABA pathways.
DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.
Adults: 150-250 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea; 200-400 mg orally once daily for shift work disorder.
Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
Clinical Note
moderateCyclophosphamide + Armodafinil
12–15 hours (terminal) in adults; longer in hepatic impairment (e.g., 20–30% increase with cirrhosis).
Terminal elimination half-life: 6-8 hours (stable metabolite). Clinical context: Twice-daily dosing typical due to pharmacokinetic profile; extended half-life compared to immediate-release amphetamine.
Renal: ~80% as metabolites (major: armodafinil acid, minor: modafinil sulfone); fecal: <1% unchanged; biliary: negligible.
Renal: 90% (unchanged drug and metabolites, primarily hippuric acid). Fecal/biliary: <1%.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Armodafinil can be decreased when combined with Cyclophosphamide."